John J Bissler

List of Publications by Year in descending order

114 papers	8,529 citations	87888 38 h-index	45317 90 g-index
115 all docs	115 docs citations	115 times ranked	6986 citing authors

#	Article	IF	Citations
1	Tsc2 mutation induces renal tubular cell nonautonomous disease. Genes and Diseases, 2022, 9, 187-200.	3.4	9
2	Acute kidney injury in pediatric hematopoietic cell transplantation: critical appraisal and consensus. Pediatric Nephrology, 2022, 37, 1179-1203.	1.7	10
3	Urinary pCO₂ Monitoring System with a Planar Severinghaus Type Sensor. Electroanalysis, 2022, 34, 1587-1597.	2.9	1
4	Single Gene Mutations in Pkd1 or Tsc2 Alter Extracellular Vesicle Production and Trafficking. Biology, 2022, 11, 709.	2.8	3
5	Cutaneous Angiomyolipoma of the Eyelid in a 2-Year-Old With Tuberous Sclerosis Complex. Journal of Neuro-Ophthalmology, 2021, 41, e69-e70.	0.8	2
6	Continuous Renal Replacement Therapy: A Review of Use and Application in Pediatric Hematopoietic Stem Cell Transplant Recipients. Frontiers in Oncology, 2021, 11, 632263.	2.8	5
7	Kidney intercalated cells and the transcription factor FOXi1 drive cystogenesis in tuberous sclerosis complex. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	14
8	Tsc Gene Locus Disruption and Differences in Renal Epithelial Extracellular Vesicles. Frontiers in Physiology, 2021, 12, 630933.	2.8	5
9	Racial Health Disparity and COVID-19. Journal of NeuroImmune Pharmacology, 2021, 16, 729-742.	4.1	7
10	Renal cystic disease in tuberous sclerosis complex. Experimental Biology and Medicine, 2021, 246, 2111-2117.	2.4	4
11	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 2021, 123, 50-66.	2.1	230
12	Leptin receptor defect with diabetes causes skeletal muscle atrophy in female obese Zucker rats where peculiar depots networked with mitochondrial damages. Ultrastructural Pathology, 2021, 45, 346-375.	0.9	1
13	Renal Involvement in Tuberous Sclerosis Complex. , 2021, , 1-12.		0
14	Congenital Lymphatic Malformation and Aortic Aneurysm in a Patient with TSC2 Mutation. Neuropediatrics, 2020, 51, 057-061.	0.6	12
15	Tuberous Sclerosis Complex Axis Controls Renal Extracellular Vesicle Production and Protein Content. International Journal of Molecular Sciences, 2020, 21, 1729.	4.1	16
16	Tuberous sclerosis complex and the kidney. , 2020, , 251-258.e3.		0
17	Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Nephrology Dialysis Transplantation, 2019, 34, 1000-1008.	0.7	31
18	A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report. Orphanet Journal of Rare Diseases, 2019, 14, 91.	2.7	36

#	Article	IF	Citations
19	Tuberous sclerosis complex exhibits a new renal cystogenic mechanism. Physiological Reports, 2019, 7, e13983.	1.7	23
20	Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells. Scientific Reports, 2019, 9, 3015.	3.3	15
21	Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma. Current Medical Research and Opinion, 2019, 35, 1103-1110.	1.9	4
22	Problems of nephrooncology. Proceedings from the 1st Scientific and Training Conference Nephrooncology 5â€“6 October 2018, GdaÅ„sk, Poland. Polish Archives of Internal Medicine, 2019, 129, 1-74.	0.4	2
23	The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatric Nephrology, 2018, 33, 101-109.	1.7	37
24	Acute Kidney Injury in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation: Incidence, Risk Factors, and Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 758-764.	2.0	39
25	Renal manifestation of tuberous sclerosis complex. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2018, 178, 338-347.	1.6	48
26	Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. PLoS ONE, 2018, 13, e0201005.	2.5	27
27	Generation, clearance, toxicity, and monitoring possibilities of unaccounted uremic toxins for improved dialysis prescriptions. American Journal of Physiology - Renal Physiology, 2018, 315, F890-F902.	2.7	5
28	Cystic Kidney Diseases Associated with Increased Cancer Risk: Tuberous Sclerosis Complex, Von Hippel-Lindau, and Birt-Hogg-DubÃ©. , 2018, , 51-66.		3
29	Outcomes of angioembolization and nephrectomy for renal angiomyolipoma associated with tuberous sclerosis complex: a real-world US national study. Current Medical Research and Opinion, 2017, 33, 821-827.	1.9	13
30	Healthcare utilization and costs in patients with tuberous sclerosiscomplex-related renal angiomyolipoma. Journal of Medical Economics, 2017, 20, 388-394.	2.1	7
31	Primary cilia regulate the osmotic stress response of renal epithelial cells through TRPM3. American Journal of Physiology - Renal Physiology, 2017, 312, F791-F805.	2.7	23
32	Natural history of patients with tuberous sclerosis complex related renal angiomyolipoma. Current Medical Research and Opinion, 2017, 33, 1277-1282.	1.9	8
33	Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS ONE, 2017, 12, e0180939.	2.5	128
34	Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex. PLoS ONE, 2017, 12, e0186235.	2.5	10
35	Measurement of glomerular filtration rate by dynamic contrast-enhanced magnetic resonance imaging using a subject-specific two-compartment model. Physiological Reports, 2016, 4, e12755.	1.7	9
36	Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. British Journal of Clinical Pharmacology, 2016, 81, 958-970.	2.4	23

#	Article	IF	Citations
37	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. Pediatric Neurology, 2016, 60, 1-12.	2.1	43
38	Long-term Clinical Morbidity in Patients With Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex. Urology, 2016, 95, 80-87.	1.0	28
39	Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. Nephron, 2016, 134, 51-58.	1.8	58
40	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 748-761.	5.6	236
41	Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review. Therapeutic Advances in Urology, 2016, 8, 279-290.	2.0	39
42	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrology Dialysis Transplantation, 2016, 31, 111-119.	0.7	120
43	Renal function after treatment for childhood cancer.. Journal of Clinical Oncology, 2016, 34, 10571-10571.	1.6	0
44	Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. European Journal of Human Genetics, 2015, 23, 1665-1672.	2.8	29
45	Therapies for polycystic kidney disease. Current Opinion in Pediatrics, 2015, 27, 227-232.	2.0	1
46	Intracranial arterial aneurysms in children and young adults. Journal of Pediatric Neuroradiology, 2015, 02, 203-235.	0.1	0
47	Rates of interventional procedures in patients with tuberous sclerosis complex-related renal angiomyolipoma. Current Medical Research and Opinion, 2015, 31, 1501-1507.	1.9	15
48	Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated. BMC Medical Genetics, 2015, 16, 39.	2.1	15
49	Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage. American Journal of Physiology - Renal Physiology, 2015, 309, F79-F87.	2.7	16
50	Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy. American Journal of Physiology - Renal Physiology, 2014, 307, F560-F570.	2.7	44
51	Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop. American Journal of Physiology - Renal Physiology, 2014, 306, F279-F283.	2.7	17
52	Characterization of Renal Toxicity in Mice Administered the Marine Biotoxin Domoic Acid. Journal of the American Society of Nephrology: JASN, 2014, 25, 1187-1197.	6.1	24
53	The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Nephrology Dialysis Transplantation, 2014, 29, 1203-1210.	0.7	79
54	Consensus Expert Recommendations for the Diagnosis and Management of Autosomal Recessive Polycystic Kidney Disease: Report of an International Conference. Journal of Pediatrics, 2014, 165, 611-617.	1.8	138

#	Article	IF	Citations
55	Performance of cystatin C-based equations in a pediatric cohort at high risk of kidney injury. Pediatric Nephrology, 2013, 28, 453-461.	1.7	36
56	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 243-254.	2.1	1,185
57	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 255-265.	2.1	693
58	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2013, 381, 817-824.	13.7	712
59	Lymphangioleiomyomatosis Screening in Women With Tuberous Sclerosis. Chest, 2013, 144, 578-585.	0.8	129
60	Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress. American Journal of Physiology - Renal Physiology, 2012, 303, F831-F844.	2.7	33
61	Impact of Ultrasound-Guided Kidney Biopsy Simulation on Trainee Confidence and Biopsy Outcomes. American Journal of Nephrology, 2012, 36, 570-574.	3.1	23
62	Replication Fork Stalling and Checkpoint Activation by a PKD1 Locus Mirror Repeat Polypurine-Polypyrimidine (Pu-Py) Tract. Journal of Biological Chemistry, 2012, 287, 33412-33423.	3.4	38
63	Real-world treatment profile for patients with tuberous sclerosis complex related angiomyolipoma: A U.S. Healthcare Claims Database study.. Journal of Clinical Oncology, 2012, 30, e15096-e15096.	1.6	0
64	Prevalence of angiomyolipoma among patients with tuberous sclerosis complex: A U.S. Healthcare Claims Database study.. Journal of Clinical Oncology, 2012, 30, e12042-e12042.	1.6	0
65	Updated safety results from EXIST-2: Everolimus therapy for angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM).. Journal of Clinical Oncology, 2012, 30, 4632-4632.	1.6	1
66	Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC): Results from EXIST-1 and EXIST-2.. Journal of Clinical Oncology, 2012, 30, 10619-10619.	1.6	2
67	Cell Cycle Control and DNA Damage Response of Conditionally Immortalized Urothelial Cells. PLoS ONE, 2011, 6, e16595.	2.5	9
68	Clinical and Molecular Insights into Tuberous Sclerosis Complex Renal Disease. Pediatric Nephrology, 2011, 26, 839-852.	1.7	51
69	Loss of Primary Cilia Upregulates Renal Hypertrophic Signaling and Promotes Cystogenesis. Journal of the American Society of Nephrology: JASN, 2011, 22, 839-848.	6.1	79
70	The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Research, 2011, 39, 7465-7476.	14.5	82
71	Polycystic Kidney Disease. , 2011, , 703-712.		0
72	Serum Vascular Endothelial Growth Factor-D Prospectively Distinguishes Lymphangioleiomyomatosis From Other Diseases. Chest, 2010, 138, 674-681.	0.8	188

#	Article	IF	Citations
73	Glomerulocystic kidney disease. Pediatric Nephrology, 2010, 25, 2049-2059.	1.7	48
74	Replication-dependent instability at (CTG)â€¢(CAG) repeat hairpins in human cells. Nature Chemical Biology, 2010, 6, 652-659.	8.0	135
75	Simulation of real-time ultrasound-guided renal biopsy. Kidney International, 2010, 78, 705-707.	5.2	22
76	Tuberous Sclerosis Complex Renal Disease. Nephron Experimental Nephrology, 2010, 118, e15-e20.	2.2	134
77	Automated Algorithm for Quantifying the Extent of Cystic Change on Volumetric Chest CT: Initial Results in Lymphangioleiomyomatosis. American Journal of Roentgenology, 2009, 192, 1037-1044.	2.2	31
78	Renal involvement in tuberous sclerosis complex and von Hippelâ€“Lindau disease: shared disease mechanisms?. Nature Reviews Nephrology, 2009, 5, 143-156.	9.6	13
79	Increased cancer risk of augmentation cystoplasty: Possible role for hyperosmolal microenvironment on DNA damage recognition. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 670, 88-95.	1.0	19
80	Nephritic factor and recurrence in the renal transplant of membranoproliferative glomerulonephritis type II. Pediatric Nephrology, 2008, 23, 1867-1876.	1.7	8
81	RecQ and RecG helicases have distinct roles in maintaining the stability of polypurineÂ·polypyrimidine sequences. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 643, 20-28.	1.0	15
82	Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis. New England Journal of Medicine, 2008, 358, 140-151.	27.0	1,138
83	Analysis of PKD1 for genomic deletion by multiplex ligation-dependent probe assay: Absence of hot spots. Genomics, 2008, 91, 203-208.	2.9	19
84	The Tuberous Sclerosis Complex Regulates Trafficking of Glucose Transporters and Glucose Uptake. American Journal of Pathology, 2008, 172, 1748-1756.	3.8	46
85	Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry. Pediatric Research, 2008, 64, 550-555.	2.3	235
86	Replication Protein A is Required for Etoposide-Induced Assembly of MRE11/RAD50/NBS1 Complex Repair Foci. Cell Cycle, 2007, 6, 2408-2416.	2.6	12
87	Cell Cycle- and Proteasome-Dependent Formation of Etoposide-Induced Replication Protein A (RPA) or Mre11/Rad50/Nbs1 (MRN) Complex Repair Foci. Cell Cycle, 2007, 6, 2399-2407.	2.6	10
88	Unstable Spinocerebellar Ataxia Type 10 (ATTCT)Â·(AGAAT) Repeats Are Associated with Aberrant Replication at the ATX10 Locus and Replication Origin-Dependent Expansion at an Ectopic Site in Human Cells. Molecular and Cellular Biology, 2007, 27, 7828-7838.	2.3	55
89	Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Human Genetics, 2007, 121, 389-400.	3.8	162
90	Triplex DNA and human disease. Frontiers in Bioscience - Landmark, 2007, 12, 4536.	3.0	53

#	Article	IF	Citations
91	Embolization of Renal Angiomyolipomata in Patients With Tuberous Sclerosis Complex. American Journal of Kidney Diseases, 2006, 47, 95-102.	1.9	95
92	DNA Structures and Genetic Instabilities Associated with Spinocerebellar Ataxia Type 10 (ATTCT) n Â·(AGAAT) n Repeats Suggest a DNA Amplification Model for Repeat Expansion. , 2006, , 447-460.		2
93	A mechanistic approach to inherited polycystic kidney disease. Pediatric Nephrology, 2005, 20, 558-566.	1.7	23
94	DNA Lesion-specific Co-localization of the Mre11/Rad50/Nbs1 (MRN) Complex and Replication Protein A (RPA) to Repair Foci. Journal of Biological Chemistry, 2005, 280, 12927-12934.	3.4	37
95	Frequency and Imaging Appearance of Hepatic Angiomyolipomas in Pediatric and Adult Patients with Tuberous Sclerosis. American Journal of Roentgenology, 2004, 182, 1027-1030.	2.2	68
96	PKD1 intron 21: triplex DNA formation and effect on replication. Nucleic Acids Research, 2004, 32, 1460-1468.	14.5	41
97	Renal angiomyolipomata. Kidney International, 2004, 66, 924-934.	5.2	266
98	Renal, hepatic, and marrow dysfunction in a patient with chronic renal insufficiency. Pediatric Nephrology, 2003, 18, 293-296.	1.7	3
99	Unpaired Structures in SCA10 (ATTCT)nÂ·(AGAAT)n Repeats. Journal of Molecular Biology, 2003, 326, 1095-1111.	4.2	90
100	Comparative evaluation of Î±-galactosidase A infusions for treatment of Fabry disease. Genetics in Medicine, 2003, 5, 144-153.	2.4	25
101	Apolipoprotein J/Clusterin Prevents a Progressive Glomerulopathy of Aging. Molecular and Cellular Biology, 2002, 22, 1893-1902.	2.3	99
102	Tuberous Sclerosis Complex: Renal Imaging Findings. Radiology, 2002, 225, 451-456.	7.3	161
103	Reduction of postembolization syndrome after ablation of renal angiomyolipoma. American Journal of Kidney Diseases, 2002, 39, 966-971.	1.9	112
104	Association between a High-Expressing Interferon-Î³ Allele and a Lower Frequency of Kidney Angiomyolipomas in TSC2 Patients. American Journal of Human Genetics, 2002, 71, 750-758.	6.2	48
105	Optimizing DpnI Digestion Conditions to Detect Replicated DNA. BioTechniques, 2002, 33, 316-318.	1.8	22
106	Infantile Dilated X-Linked Cardiomyopathy, G4.5 Mutations, Altered Lipids, and Ultrastructural Malformations of Mitochondria in Heart, Liver, and Skeletal Muscle. Laboratory Investigation, 2002, 82, 335-344.	3.7	57
107	DNA inverted repeats and human disease. Frontiers in Bioscience - Landmark, 1998, 3, d408-418.	3.0	55
108	C1 Inhibitor Gene Sequence Facilitates Frameshift Mutations. Molecular Medicine, 1998, 4, 795-806.	4.4	9

#	Article	IF	Citations
109	Antibody to C1Ì„-inhibitor in a patient receiving C1Ì„-inhibitor infusions for treatment of hereditary angioneurotic edema with systemic lupus erythematosus reacts with a normal allotype of residue 458 of C1Ì„-inhibitor. Translational Research, 1996, 128, 438-443.	2.3	17
110	Contiguous deletion and duplication mutations resulting in type 1 hereditary angioneurotic edema. Human Genetics, 1994, 93, 265-269.	3.8	31
111	[6] C1 Inhibitor. Methods in Enzymology, 1993, 223, 97-120.	1.0	13
112	C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nature Genetics, 1992, 1, 354-358.	21.4	68
113	Paradoxical hypertension in hypovolemic children. Pediatric Emergency Care, 1991, 7, 350-352.	0.9	5
114	Alimentary Tract Duplications in Children. Clinical Pediatrics, 1988, 27, 152-157.	0.8	45